Mycronic Q4’20: Guidance and Order Intake Well Below Estimates
Redeye notes that Mycronic reports Q4 EBIT above our estimates, but overall the report is weaker than expected, primarily relating to the 2021 sales guidance of SEK 3. 9 bn (expected 4. 3 bn) and the order intake growth of -34% in Assembly Solutions (expected -15%). However, the separate reporting of the AS divisions is a crucial, positive data point.